Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
ANGLE plc ( (GB:AGL) ) has provided an announcement.
ANGLE plc announced the successful completion of assay development projects for AstraZeneca, including the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay. These assays are now approved for use and position ANGLE to conduct large-scale clinical trials, enhancing its market opportunities in the growing AR and DDR therapeutic markets. Additionally, ANGLE completed a Phase 2 pilot study with Eisai, demonstrating the Parsortix system’s ability to dynamically assess HER2 status in breast cancer patients, which could significantly impact HER2-ADC clinical trials. Despite Eisai not progressing with the BB-1701 drug, ANGLE maintains a strong relationship with them and is exploring further collaborations.
More about ANGLE plc
ANGLE plc is a leading liquid biopsy company specializing in circulating tumor cell (CTC) solutions for research, drug development, and clinical oncology. The company offers clinical services and diagnostic products through its Parsortix system, which is FDA cleared and used for complete downstream analysis of blood samples.
YTD Price Performance: -4.88%
Average Trading Volume: 1,401,673
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £29.03M
Learn more about AGL stock on TipRanks’ Stock Analysis page.